Compare SEM & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEM | SNDX |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2008 | 2014 |
| Metric | SEM | SNDX |
|---|---|---|
| Price | $16.30 | $23.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $15.17 | ★ $37.92 |
| AVG Volume (30 Days) | ★ 3.2M | 1.3M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | $5.45 | $107.40 |
| Revenue Next Year | $4.78 | $43.28 |
| P/E Ratio | $14.04 | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $11.65 | $8.59 |
| 52 Week High | $18.61 | $25.59 |
| Indicator | SEM | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 56.73 |
| Support Level | $16.20 | $19.46 |
| Resistance Level | $16.59 | $25.38 |
| Average True Range (ATR) | 0.03 | 1.12 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 70.00 | 48.90 |
Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.